Anders Frid
Research Subjects
Research Interests
Anders Frid has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Anders Andersson
Department of Clinical Chemistry and Pharmacology, University Hospital of Lund, Lund, Sweden
2 shared publicationsAnne Cato
Department of Clinical Chemistry and Pharmacology, University Hospital of Lund, Lund, Sweden
2 shared publicationsEllen Vinge
Department of Clinical Chemistry and Pharmacology, University Hospital of Lund, Lund, Sweden
2 shared publicationsGunnar Sterner
2 shared publications- Kerstin Berntorp
Department of Clinical Sciences, Division of Endocrinology, Skåne University Hospital, Malmö, Lund University, Lund, Sweden
2 shared publications Magnus Löndahl
Department of Endocrinology, University Hospital of Lund, Lund, Sweden
2 shared publications
Latest Publications
- Open Access
Effect of Oral Pre-Meal Administration of Betaglucans on Glycaemic Control and Variability in Subjects with Type 1 Diabetes
We conducted a double-blind placebo-controlled crossover pilot study to investigate the effect of oat betaglucans (β-glucan) on glycaemic control and variability in adults with type 1 diabetes (T1D; n = 14). Stomacol® tablets (1.53 g of β-glucan) or placebo (Plac) were administered three times daily before meals for two weeks. Glucose levels were monitored during the second week by continuous glucose monitoring (CGM). There was an increase in basic measures of glycaemic control (maximal glucose value 341 ± 15 vs. 378 ± 13 mg/dL for Plac and β-glucan, p = 0.004), and average daily risk range (62 ± 5 vs. 79 ± 4 mg/dL for Plac and β-glucan, p = 0.003) favouring Plac over β-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures. Basic measures of glucose variability were also slightly increased during β-glucan treatment, with no difference in more complex measures. However, glycaemic variability increased between the first and last two CGM days on Plac, but remained unchanged on β-glucan. In conclusion, in this pilot study we were unable to demonstrate a general positive effect of β-glucan before meals on glucose control or variability in T1D.
Open AccessEffect of Oral Pre-Meal Administration of Betaglucans on Glycaemic Control and Variability in Subjects with Type 1 Diabetes
We conducted a double-blind placebo-controlled crossover pilot study to investigate the effect of oat betaglucans (β-glucan) on glycaemic control and variability in adults with type 1 diabetes (T1D; n = 14). Stomacol® tablets (1.53 g of β-glucan) or placebo (Plac) were administered three times daily before meals for two weeks. Glucose levels were monitored during the second week by continuous glucose monitoring (CGM). There was an increase in basic measures of glycaemic control (maximal glucose value 341 ± 15 vs. 378 ± 13 mg/dL for Plac and β-glucan, p = 0.004), and average daily risk range (62 ± 5 vs. 79 ± 4 mg/dL for Plac and β-glucan, p = 0.003) favouring Plac over β-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures. Basic measures of glucose variability were also slightly increased during β-glucan treatment, with no difference in more complex measures. However, glycaemic variability increased between the first and last two CGM days on Plac, but remained unchanged on β-glucan. In conclusion, in this pilot study we were unable to demonstrate a general positive effect of β-glucan before meals on glucose control or variability in T1D.
- Open Access
- 17 August 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 329
Antibodies against gonadotropin-releasing hormone (GnRH) in patients with diabetes mellitus is associated with lower body weight and autonomic neuropathy
Background: Esophageal dysmotility and gastroparesis are common secondary complications in patients with diabetes mellitus. Patients with dysmotility express antibodies against gonadotropin-releasing hormone (GnRH) in serum. The aim of the present study was to scrutinize patients with diabetes mellitus with regard to the presence of GnRH antibodies, and to examine associations between antibodies and clinical findings. Results: Thirty-nine consecutive patients with diabetes mellitus were included in the study after clinical examination and examination by esophageal manometry and gastric emptying scintigraphy. Serum was analyzed for the presence of antibodies against GnRH using an ELISA, and values are expressed as relative units (RU). Two age- and gender-matched healthy subjects per each patient served as controls. The prevalence of IgM GnRH antibodies in patients was 33% compared to 14% in controls (p = 0.027), with a higher antibody titer; 1.2 (0.6-5.0) and 0.2 (0.1-0.3) RU, respectively (p = 0.000). The expression of IgG antibodies was 15% in patients and none in controls (p = 0.000). Lower body mass index was associated with the presence of IgM antibodies (OR = 0.835, 95% CI = 0.699–0.998), and autonomic neuropathy with the presence IgG antibodies (OR = 9.000, 95% CI = 1.327–61.025). Esophageal dysmotility (69%) or gastroparesis (18%) were not associated with the presence of IgM antibodies (OR = 0.589, 95% CI = 0.143–2.424 and OR = 3.407, 95% CI = 0.633–18.350, respectively). Neither was esophageal dysmotility associated with IgG antibodies (OR = 2.500, 95% CI = 0.259–24.096). Conclusions: Antibodies against GnRH are more common in patients with diabetes mellitus compared with healthy controls. IgM antibodies are associated with lower body mass index and IgG antibodies are associated with autonomic neuropathy.
- 17 August 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 329
Open AccessAntibodies against gonadotropin-releasing hormone (GnRH) in patients with diabetes mellitus is associated with lower body weight and autonomic neuropathy
Background: Esophageal dysmotility and gastroparesis are common secondary complications in patients with diabetes mellitus. Patients with dysmotility express antibodies against gonadotropin-releasing hormone (GnRH) in serum. The aim of the present study was to scrutinize patients with diabetes mellitus with regard to the presence of GnRH antibodies, and to examine associations between antibodies and clinical findings. Results: Thirty-nine consecutive patients with diabetes mellitus were included in the study after clinical examination and examination by esophageal manometry and gastric emptying scintigraphy. Serum was analyzed for the presence of antibodies against GnRH using an ELISA, and values are expressed as relative units (RU). Two age- and gender-matched healthy subjects per each patient served as controls. The prevalence of IgM GnRH antibodies in patients was 33% compared to 14% in controls (p = 0.027), with a higher antibody titer; 1.2 (0.6-5.0) and 0.2 (0.1-0.3) RU, respectively (p = 0.000). The expression of IgG antibodies was 15% in patients and none in controls (p = 0.000). Lower body mass index was associated with the presence of IgM antibodies (OR = 0.835, 95% CI = 0.699–0.998), and autonomic neuropathy with the presence IgG antibodies (OR = 9.000, 95% CI = 1.327–61.025). Esophageal dysmotility (69%) or gastroparesis (18%) were not associated with the presence of IgM antibodies (OR = 0.589, 95% CI = 0.143–2.424 and OR = 3.407, 95% CI = 0.633–18.350, respectively). Neither was esophageal dysmotility associated with IgG antibodies (OR = 2.500, 95% CI = 0.259–24.096). Conclusions: Antibodies against GnRH are more common in patients with diabetes mellitus compared with healthy controls. IgM antibodies are associated with lower body mass index and IgG antibodies are associated with autonomic neuropathy.
- 3 July 2013
- Vol. 110 (22) , 1100-2
[Patients with ischemic heart disease often suffers from diabetes].
- 3 July 2013
- Vol. 110 (22) , 1100-2
[Patients with ischemic heart disease often suffers from diabetes].
- Open Access
- 9 March 2010
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (6) , 1291-1293
Novel Assay of Metformin Levels in Patients With Type 2 Diabetes and Varying Levels of Renal Function
OBJECTIVE: To study trough levels of metformin in serum and its intra-individual variation in patients using a newly developed assay. RESEARCH DESIGN AND METHODS: Trough serum levels of metformin were measured once using liquid chromatography–tandem mass spectrometry (LCMSMS) in 137 type 2 diabetic patients with varying renal function (99 men) and followed repeatedly during 2 months in 20 patients (16 men) with estimated glomerular filtration rate (eGFR) 60, 30–60, and 20 μmol/l. Metformin measurement is less suitable for dose titration.
- 9 March 2010
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (6) , 1291-1293
Open AccessNovel Assay of Metformin Levels in Patients With Type 2 Diabetes and Varying Levels of Renal Function
OBJECTIVE: To study trough levels of metformin in serum and its intra-individual variation in patients using a newly developed assay. RESEARCH DESIGN AND METHODS: Trough serum levels of metformin were measured once using liquid chromatography–tandem mass spectrometry (LCMSMS) in 137 type 2 diabetic patients with varying renal function (99 men) and followed repeatedly during 2 months in 20 patients (16 men) with estimated glomerular filtration rate (eGFR) 60, 30–60, and 20 μmol/l. Metformin measurement is less suitable for dose titration.
- 9 April 2009
- Vol. 106 (7) , 428-9
[Metformin in serum. Results of a study as basis for preliminary therapeutic recommendations].
- 9 April 2009
- Vol. 106 (7) , 428-9
[Metformin in serum. Results of a study as basis for preliminary therapeutic recommendations].
- 20 June 2008
- Vol. 105, 1310, 1312
[Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
- 20 June 2008
- Vol. 105, 1310, 1312
[Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
- Open Access
- 30 April 2008
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 7 (1) , 12
Treatment with pioglitazone induced significant, reversible mitral regurgitation
There has in recent years been great concern about possible cardiac side effects of thiazolidinediones (TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.
- 30 April 2008
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 7 (1) , 12
Open AccessTreatment with pioglitazone induced significant, reversible mitral regurgitation
There has in recent years been great concern about possible cardiac side effects of thiazolidinediones (TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.
- 30 September 2006
- Vol. 103 (36) , 2560-2
[Four cases of lactic acidosis following metformin treatment].
- 30 September 2006
- Vol. 103 (36) , 2560-2
[Four cases of lactic acidosis following metformin treatment].
- 23 September 2004
- Vol. 101 (39) , 3014
[Documented advantages of insulin Lantus when compared with NPH insulin].
- 23 September 2004
- Vol. 101 (39) , 3014
[Documented advantages of insulin Lantus when compared with NPH insulin].